Jonathan Freve

Jonathan Freve (finance chief) discloses dealings in 2 companies, chiefly F-star Therapeutics, Inc. and Damora Therapeutics, Inc. Between 4 August 2016 and 3 December 2021, the trades on record add up to 9 filings.

Every open-market trade on record is a purchase: 8 purchases worth €92k, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 1 share grant. So far in 2021, the count stands at 4 purchases and no sales.

Half of the purchases are above €9,160 and half below. Clusters matter here: 6 out of 8 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The record was last updated on 6 December 2021 with an open-market purchase (€8,809) in Damora Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.